By Ben Glickman
Shares of NewAmsterdam Pharma slid Monday after the Dutch company named a new chief financial officer.
The stock was down 9.6% to $6.38 in afternoon trading. Shares are down about 42% this year.
The clinical-stage biopharmaceutical company said Ian Somaiya would step in as CFO. Somaiya most recently served as CFO of Elucida Oncology and has more than 25 experience in leadership roles in the biopharmaceutical industry.
Somaiya succeeds Louise Kooij, who stepped into the role on an interim basis after previous CFO David Topper resigned in March.
Write to Ben Glickman at ben.glickman@wsj.com
Read the full article here